← Leaderboards
Paul Haluska
Mayo Clinic Rochester
$2,010,168
Attributed
$2,290,167
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2012–19$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,290,167 · 4
By mechanism
P50$1,108,563 · 2
R01$621,606 · 1
UM1$559,998 · 1
Top collaborators
- Charles Erlichman1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Kah-Whye Peng$11,311,466
- Saravut Weroha$5,625,190
- Asish Kumar Ghosh$2,307,685
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseBaseResistanceFundingXenograft ProcedureCollectionMolecularClinicScid MiceProgramsResourcesSourceNovel TherapeuticsCharacteristicsOvarianImmune SystemHistologicInvestigationMalignant Neoplasm Of OvaryEvaluationMonitorGene Expression ProfileIn Vivo
Grant awards (8)
Core D - Animal Models Core$181,306
P50 · FY2019 · CA · contact PI
Core D - Animal Models Core$148,438
P50 · FY2018 · CA · contact PI
Core D - Animal Models Core$149,342
P50 · FY2017 · CA · contact PI
Core D - Animal Models Core$138,765
P50 · FY2016 · CA · contact PI
Core D - Animal Models Core$127,738
P50 · FY2015 · CA · contact PI
(PQD5) Avatar-directed Treatment for Ovarian Cancer$621,606
R01 · FY2014 · CA · contact PI
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis$559,998
UM1 · FY2014 · CA · contact PI
Regulation of Hormone Resistant Breast Cancer by IGF and Insulin System$362,974
P50 · FY2012 · CA · contact PI